HRP20231446T1 - Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma - Google Patents
Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma Download PDFInfo
- Publication number
- HRP20231446T1 HRP20231446T1 HRP20231446TT HRP20231446T HRP20231446T1 HR P20231446 T1 HRP20231446 T1 HR P20231446T1 HR P20231446T T HRP20231446T T HR P20231446TT HR P20231446 T HRP20231446 T HR P20231446T HR P20231446 T1 HRP20231446 T1 HR P20231446T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- dose
- administered
- day
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 201000000980 schizophrenia Diseases 0.000 title claims 2
- 150000003950 cyclic amides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 28
- 208000024891 symptom Diseases 0.000 claims 5
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 2
- 229940127236 atypical antipsychotics Drugs 0.000 claims 2
- 239000003176 neuroleptic agent Substances 0.000 claims 2
- 230000000701 neuroleptic effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 206010014557 Emotional poverty Diseases 0.000 claims 1
- 206010041243 Social avoidant behaviour Diseases 0.000 claims 1
- 230000000698 schizophrenic effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0003—Two-dimensional division
- H04L5/0005—Time-frequency
- H04L5/0007—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
- H04L5/001—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0014—Three-dimensional division
- H04L5/0016—Time-frequency-code
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0014—Three-dimensional division
- H04L5/0016—Time-frequency-code
- H04L5/0019—Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
- H04L5/005—Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0053—Allocation of signalling, i.e. of overhead other than pilot signals
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Signal Processing (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36607510P | 2010-07-20 | 2010-07-20 | |
| EP16181339.9A EP3135286B1 (en) | 2010-07-20 | 2011-07-20 | Methods of use of cyclic amide derivatives to treat schizophrenia and symptoms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231446T1 true HRP20231446T1 (hr) | 2024-03-01 |
Family
ID=45497166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231446TT HRP20231446T1 (hr) | 2010-07-20 | 2011-07-20 | Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20180155318A1 (enExample) |
| EP (4) | EP4494704A3 (enExample) |
| JP (2) | JP6053678B2 (enExample) |
| KR (1) | KR101867633B1 (enExample) |
| CN (1) | CN103220910B (enExample) |
| BR (1) | BR112013001303A2 (enExample) |
| CA (2) | CA3117855C (enExample) |
| DK (2) | DK3135286T3 (enExample) |
| ES (2) | ES2656313T3 (enExample) |
| FI (1) | FI3135286T3 (enExample) |
| HR (1) | HRP20231446T1 (enExample) |
| HU (1) | HUE064157T2 (enExample) |
| LT (1) | LT3135286T (enExample) |
| NO (1) | NO2595484T3 (enExample) |
| PL (2) | PL3135286T3 (enExample) |
| PT (2) | PT3135286T (enExample) |
| RS (1) | RS64819B1 (enExample) |
| RU (1) | RU2576611C2 (enExample) |
| SI (1) | SI3135286T1 (enExample) |
| SM (1) | SMT202300413T1 (enExample) |
| TW (1) | TWI583679B (enExample) |
| WO (1) | WO2012012542A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058212T2 (hu) * | 2014-12-02 | 2022-07-28 | Minerva Neurosciences Inc | 2-((1-(2(4-fluorfenil)-2-oxoetil)piperidin-4-il)metil)izoindolin-1-ont tartalmazó készítmények skizofrénia kezelésére |
| CN113908156A (zh) * | 2016-05-25 | 2022-01-11 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| IL308650B2 (en) | 2017-06-21 | 2025-08-01 | Minerva Neurosciences Inc | Gastro-resistant controlled release oral dosage forms |
| MY198713A (en) | 2017-10-10 | 2023-09-19 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| EP3840835A1 (en) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3888340T2 (de) * | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit. |
| NZ235841A (en) * | 1989-10-27 | 1993-03-26 | Du Pont | (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions |
| CA2069318A1 (en) * | 1989-10-27 | 1991-04-28 | Engelbert Ciganek | (n-phthalimidoalkyl) piperidines |
| AU2001234175B2 (en) * | 2000-02-29 | 2004-10-07 | Mitsubishi Pharma Corporation | Novel cyclic amide derivatives |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
| AU2006256583B2 (en) * | 2005-06-06 | 2012-01-12 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as GlyT1 inhibitors to treat schizophrenia |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 NO NO11810349A patent/NO2595484T3/no unknown
- 2011-07-20 RS RS20231061A patent/RS64819B1/sr unknown
- 2011-07-20 SI SI201132096T patent/SI3135286T1/sl unknown
- 2011-07-20 HU HUE16181339A patent/HUE064157T2/hu unknown
- 2011-07-20 WO PCT/US2011/044697 patent/WO2012012542A1/en not_active Ceased
- 2011-07-20 ES ES11810349.8T patent/ES2656313T3/es active Active
- 2011-07-20 CN CN201180045067.1A patent/CN103220910B/zh active Active
- 2011-07-20 DK DK16181339.9T patent/DK3135286T3/da active
- 2011-07-20 BR BR112013001303A patent/BR112013001303A2/pt not_active Application Discontinuation
- 2011-07-20 FI FIEP16181339.9T patent/FI3135286T3/fi active
- 2011-07-20 EP EP24197877.4A patent/EP4494704A3/en active Pending
- 2011-07-20 PT PT161813399T patent/PT3135286T/pt unknown
- 2011-07-20 ES ES16181339T patent/ES2963362T3/es active Active
- 2011-07-20 EP EP16181339.9A patent/EP3135286B1/en active Active
- 2011-07-20 DK DK11810349.8T patent/DK2595484T3/en active
- 2011-07-20 PL PL16181339.9T patent/PL3135286T3/pl unknown
- 2011-07-20 SM SM20230413T patent/SMT202300413T1/it unknown
- 2011-07-20 JP JP2013520840A patent/JP6053678B2/ja active Active
- 2011-07-20 CA CA3117855A patent/CA3117855C/en active Active
- 2011-07-20 PT PT118103498T patent/PT2595484T/pt unknown
- 2011-07-20 EP EP17196800.1A patent/EP3335731B1/en active Active
- 2011-07-20 TW TW100125661A patent/TWI583679B/zh active
- 2011-07-20 PL PL11810349T patent/PL2595484T3/pl unknown
- 2011-07-20 HR HRP20231446TT patent/HRP20231446T1/hr unknown
- 2011-07-20 EP EP11810349.8A patent/EP2595484B1/en active Active
- 2011-07-20 CA CA2806017A patent/CA2806017C/en active Active
- 2011-07-20 LT LTEP16181339.9T patent/LT3135286T/lt unknown
- 2011-07-20 RU RU2013107382/15A patent/RU2576611C2/ru active
- 2011-07-20 KR KR1020137004217A patent/KR101867633B1/ko active Active
-
2016
- 2016-08-23 JP JP2016163049A patent/JP6200561B2/ja active Active
-
2017
- 2017-07-21 US US15/656,062 patent/US20180155318A1/en not_active Abandoned
-
2022
- 2022-05-16 US US17/745,024 patent/US20220274951A1/en not_active Abandoned
-
2024
- 2024-08-30 US US18/821,656 patent/US20250179044A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| SI2889033T1 (en) | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| HRP20231446T1 (hr) | Postupci upotrebe derivata cikličkih amida za liječenje shizofrenije i njezinih simptoma | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| UA124922C2 (uk) | Модулятори ядерного транспорту та їх застосування | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| HRP20150982T1 (hr) | Novi modulatori sfingozin fosfat receptora | |
| HRP20180425T1 (hr) | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| EP2726066A4 (en) | DOSE FORMS FOR ORAL ADMINISTRATION AND TREATMENT METHODS THEREWITH | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| HRP20180341T1 (hr) | Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| ME02474B (me) | Terapijski režimi | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| CL2013003556A1 (es) | Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias | |
| JP2013531072A5 (enExample) |